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A number of recent observations have brought in-
to question a possible role for the somatomedins in
explaining the growth failure which characterizes
chronic renal disease in childhood [1—51. In order to
put these findings into perspective, it is necessary
first to review the status of these peptides as media-
tors of growth and the wide variety of techniques
which have been used to measure the levels of these
substances in serum.
The nature of the somatomedins
The somatomedins are a family of growth-hor-
mone-dependent, insulin-like peptides which have
been postulated to mediate the actions of pituitary
growth hormone on skeletal tissue. Their exact
physiologic role, however, remains the subject of
controversy since a convincing demonstration has
not yet been made that any of the somatomedins
will restore growth when administered to a by-
pophysectomized animal.
The existence of these peptides was first sug-
gested by the pioneering observations of Salmon
and Daughaday in 1957 [6], that cartilage is not af-
fected by direct exposure to growth hormone itself
in vitro, but is responsive to one or more substances
which appear in serum after growth hormone
administration. This growth-hormone-dependent
serum activity was initially called "sulfation fac-
tor" because of its capacity to stimulate sulfate in-
corporation into proteoglycans of cartilage. This ac-
tion, however, later proved to be but one manifesta-
tion of the growth-promoting effect of the "sulfation
factor." In cartilage, it also stimulates the synthesis
of RNA and DNA as well as collagen and other pro-
teins; in muscle and adipose tissue, it mimics the
action of insulin; and, in cell culture, it stimulates
DNA synthesis and mitosis in a variety of cell lines.
For these reasons, the constrictive term "sulfation
factor" has been replaced by the more general des-
ignation "somatomedin" [71.
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Four peptides have been described which fulfill
the definition of a somatomedin: somatomedin-A,
somatomedin-D, nonsuppressible insulin-like activ-
ity-soluble (NSILA-S), and multiplication-stimulat-
ing activity (MSA) [81. Although these four sub-
stances are small peptides with molecular weights
between 5,500 and 8,500 daltons, it is still unclear
whether each of these somatornedins is a different
substance or whether some of them may be dif-
ferent names for the same peptide.
The somatomedins constitute only one category
in the larger group of peptide growth factors that
has been recognized within recent years. There is
increasing evidence that these factors collectively
play a large role in the hierarchy of growth-regulat-
ing mechanisms. The broad spectrum growth fac-
tors which stimulate cell division in a wide variety
of cell types include fibroblast growth factor, epi-
dermal growth factor, and the somatomedins. Ex-
amples of more specialized growth factors which
act on highly specific cell types are erythropoietin,
nerve growth factor, and thymosine [9].
Under many circumstances, the concentration of
somatomedin in serum accurately reflects growth
hormone status and frequently correlates better
with linear growth rates of children than do direct
measurements of growth hormone itself [10, 111.
There are circumstances, however, where the rela-
tionship between somatomedin and growth hor-
mone levels are paradoxical. The most striking ex-
ample of this is in starvation and protein-calorie
malnutrition, where growth hormone levels are
greatly elevated, whereas somatomedin levels are
severely depressed [12—151. A similar relationship
between growth hormone and somatomedin is
found in the genetic form of dwarfism described by
Laron et al [161, in which a clinical syndrome simi-
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lar to hypopituitary dwarfism is produced by end-
organ refractoriness to the action of growth hor-
mone. Although most laboratories have agreed on
the major trends of somatomedin activity in a wide
variety of clinical conditions, widely discrepant val-
ues have been reported in certain clinical condi-
tions, most notably in starvation and in severe renal
disease, To understand the reason for these dis-
crepancies, it is necessary to review the analytic
techniques which have been used to estimate soma-
tomedin levels in the serum.
Measurement of somatomedins
By bioassay. Most of the bioassays which have
been used to measure somatomedin have been de-
pendent on either the incorporation of radioactive
chondroitin sulfate (35S04) into cartilage or the in-
corporation of tritiated thymidine into DNA.
Daughaday's original assay, which utilized cartilage
from hypophysectomized rats, has been modified
by many investigators in attempts to improve repro-
ducibility and precision. These modifications have
included the use of cartilage from a single hypophy-
sectomized rat [17] and the use of cartilage seg-
ments from fasted immature rats [18, 19]. Hall,
Holmgren, and Lindahl [20] substituted pelvic leaf-
lets from il-day-old chick embryos for rat cartilage,
and Van den Brande and DuCaju [15] developed an
assay using uniform pieces of pig rib cartilage. Phil-
lips, Herington, and Daughaday [21] stressed the
importance of acquiring cartilage from pigs less
than 9 months of age.
Although there is no evidence that any of these
bioassays discriminate differentially among the dif-
ferent somatomedins, all of the cartilage bioassays
suffer from inherent imprecision and from the fact
that a variety of substances present in the serum
may exert inhibitory effects on either sulfate or
thymidine incorporation into cartilage. Salmon has
studied the nature of these inhibitors both in hy-
pophysectomized and starved rats and has found
that at least part of the inhibitory material is heat-
labile, nondialyzable, and destroyed by trypsin di-
gestion [22]. Van den Brande and DuCajo have sug-
gested that bioassayable somatomedin levels may
be falsely depressed by such inhibition in protein
calorie malnutrition [151, but Grant et al have dis-
puted this finding and believe somatomedin levels
to be authentically low in this condition [12].
There is now evidence (Furlanetto RW and Van-
Wyk JJ, unpublished data) that the depressed soma-
tomedin levels found in children receiving high-
dose glucocorticoid therapy are due to a direct
depressing effect of the corticosteroids in serum on
cartilage tissue. Bioassays based on the uptake of
SO4 into cartilage are also subject to serious error
if the total concentration of sulfate in serum is not
taken into consideration. This is a particularly seri-
otis source of error in renal disease where the serum
sulfate concentration may be markedly elevated [5].
Wiedemann et al [23] have shown that heparin false-
ly elevates somatomedin levels in cartilage bioas-
says.
Radioreceptor assays. Each of the four soma-
tomedins has been found to compete with '2I-in-
sulin for binding to the insulin receptor in a variety
of cell membranes. In addition, each of the radio-
labeled somatomedins hinds to specific somatome-
din cell membrane receptors distinct from the in-
sulin receptor. These receptor interactions have
served as a basis for competitive membrane-binding
assays to measure somatomedin levels in serum.
Although radioreceptor assays are not subject to
distortion because of inhibitors and variances in sul-
fate concentration in the serum, there is reason to
believe that some of these radioligand-binding as-
says may measure different populations of sub-
stances in serum. In spite of the theoretical advan-
tages over bioassays (lack of influence of inorganic
sulfate, steroids, and cartilage inhibitors), dis-
crepancies obtained in different laboratories with
the respective radioligands have often been greater
than those obtained with bioassays.
Radioimmunoassays. Specific radioimmunoas-
says have now been developed for NSILA-S and
somatomedin-C. Furlanetto et al [24] have reported
that the serum values obtained with the radioimmu-
noassay for somatomedin-C exhibit greater growth
hormone dependence than any of the other assays.
Whereas by other assay techniques, hypopituitary
patients have serum levels 20 to 40% of normal, lev-
els of somatomedin-C by radioimmunoassay are
much less than this and are often undetectable. Sim-
ilarly, patients with acromegaly have much higher
serum somatomedin-C levels by radioimmunoassay
than do those obtained with any other technique.
The levels of somatomedin-C by radioimmunoassay
in protein calorie malnutrition are undetectable un-
til the state of nutrition is improved. This technique
has not yet been used to study children with chronic
renal failure.
,So,,ialo,nedi,i—hindm' proteins
Although steroid hormones and thyroxine are
transported in serum on large binding proteins,
somatomedin is as yet the only known peptide hor-
mone with a large molecular weight binding protein.
It has even been suggested that it is the binding pro-
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tein that is under growth hormone control rather
than somatomedin itself. In any event, there is no
detectable free somatomedin in serum and very
little somatomedin is excreted in urine. For this rea-
son, measurements of total somatomedin in serum
may not reflect the proportion of free somatomedin
(if any) which might be available to the cells in-
volved in growth. In the fetus and young child, total
somatomedin levels are low even though these are
the periods of most rapid growth [24, 25}.
Somatomedin in chronic rena/disease
Serum levels of somatomedin as measured by
bioassay may be decreased in children with end-
stage renal failure associated with growth failure
[1], while growth hormone levels are either normal
or increased (1, 26). Saenger et al [1] measured
somatomedin by bioassay in nine growth-retarded
uremic male children before and following renal
transplantation. Serum somatomedin levels were
corrected for sulfate concentrations in this study.
Before transplantation, somatomedin levels were
low in all children (in the hypopituitary range). Fol-
lowing renal transplantation, there was a significant
linear correlation between growth velocity cor-
rected for bone age and somatomedin levels as well
as creatinine clearance. Somatomedin levels after
transplantation were not statistically different from
the somatomedin levels of eight healthy male con-
trol subjects matched for bone age. Growth hor-
mone levels were normal following transpianation.
Phillips et al and Pennisi et al [3, 27] found sulfate
concentrations in uremic children to be 7 to 22 times
normal before dialysis and 3 to 12 times normal af-
ter dialysis. When somatomedin levels were calcu-
lated without correction for sulfate, 9 out of 10 chil-
dren had undetectable levels before dialysis. When
these authors corrected somatomedin levels for sul-
fate content in the serum, somatomedin levels were
below the normal range in 4 of 10 children. Follow-
ing dialysis, corrected somatomedin levels in-
creased an average of 75% and were within the nor-
mal range in all. Wiedemann et al have recently sug-
gested that the observed rise in somatomedin
following dialysis may be related to heparinization
[231. Although Phillips et al [3] also found that hepa-
rinization increased somatomedin measurement,
they argued that this could only account for 25% of
their observed increases in somatomedin levels fol-
lowing dialysis. These authors suggested that dial-
ysis may remove somatomedin inhibitors [281.
The radioreceptor assay for somatomedin has
produced somewhat different results in children
with chronic renal failure. Arnold et al [291 studied
23 children with varying degrees of chronic renal
failure; 15 had glomerular filtration rates less than
50 mllminll.73 m2, and 5 were Ofl hemodialysis. No
correlation was found between somatomedin A lev-
els as measured by the radioreceptor assay and gb-
merular filtration rates. Somatomedin A levels were
higher in children of all ages than they were in
adults. Children with renal disease with glomerular
filtration rates of less than 50 mllmin had somatome-
din A levels that were similar to those of normal
children. The five children who were on hemo-
dialysis, however, had somatomedin A levels that
were three times those of normal pediatric controls.
Children undergoing peritoneal dialysis had normal
somatomedin A levels. These authors observed a
correlation between somatomedin A levels and ca-
loric intake in uremic and normal children.
The finding of a correlation between somatome-
din levels and nutritonal status is reminiscent of the
studies of kwashiorkor by Grant et al [12]. Correc-
tion of this nutritional deficit in these children re-
sulted in a rise of somatomedin levels (measured by
bioassay) to normal.
Somatomedin levels in children with chronic re-
nal failure have thus been found to be low, normal,
or high in various laboratories by various assays.
Bioassays, even when corrected for sulfate content,
have tended to give normal or low values in children
with chronic renal failures, whereas radioreceptor
assays have tended to give high values. The effect
of hemodialysis in removing inhibitors of soma-
tornedin remains to be clarified. It is clear that more
work needs to be done regarding the technical as-
pects of somatomedin measurement. The radioim-
munoassay that has recently been developed may
improve this technology [24]. The clinician caring
for children with growth failure and the clinical in-
vestigator had best wait until those with technical
expertise in this field resolve these difficulties be-
fore drawing firm conclusions as to the level of
somatomedin in renal failure associated with
growth failure in children.
An area which has received all too little attention
is end-organ resistance to the action of growth hor-
mone-dependent (and independent?) somatome-
dins. The relationship of the assayable somatome-
din to its in vivo effect on the target tissue (carti-
lage, bone) in the promotion of linear growth is
unclear. To understand the action of the somatome-
dins, we must distinguish between their effect on
cell proliferation in a biological assay and the effect
on differentiated cell functions which are character-
istic of the target cells. We must now turn our atten-
tion to careful studies of the target tissues.
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Summary
The somatomedins are a family of growth hor-
mone-dependent insulin-like peptides which have
been postulated to mediate the actions of pituitary
growth hormone on skeletal tissue. The somatome-
din peptides are part of a larger family of growth
factors. Somatomedin has been measured by
bioassays, by radioreceptor assays, and recently by
a radioimmunoassay. Bioassays are influenced by
glucocorticoids, sulfate, heparin, and other inhib-
itors; radioreceptor assays from different laborato-
ries presently give conflicting results but early expe-
rience with the immunoassay is promising. Soma-
tomedin levels are low in hypopituitary states, in
malnutrition, and in general when growth hormone
is low. Somatomedin's levels in uremia are various-
ly reported. Most bioassays report low values, al-
though the hole of inhibitors is not clear. Values by
radioreceptor assays are normal or elevated, but
their specificity is unproven. No data are available
using radioimmunoassay. No study has addressed
end-organ responsivity in uremia.
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